13F Holdings
中文EN

CORT CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1088856 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY30.0%
TTM net income YoY52.9%
TTM EPS YoY52.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR21.1%

Margins

Gross margin98.5%
Operating margin11.5%
Net margin16.8%
FCF margin20.2%
EBITDA margin11.8%

Returns

ROE22.1%
ROA17.5%
ROIC (approx.)17.9%
Asset turnover1.04x

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.00x
Current ratio3.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.22x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$761.41M$675.04M$482.38M$401.86M$365.98M
Cost of revenue$12.98M$10.88M$6.48M$5.38M$5.28M
Gross profit$748.43M$664.16M$475.89M$396.47M$360.70M
R&D expense$254.91M$246.89M$184.35M$130.99M$113.86M
SG&A expense$448.73M$280.32M$184.26M$152.85M$122.36M
Operating income$44.80M$136.95M$107.28M$112.63M$124.48M
Pretax income$66.46M$161.49M$124.56M$116.19M$125.01M
Income tax-$33.19M$20.28M$18.42M$14.77M$12.49M
Net income$99.65M$141.21M$106.14M$101.42M$112.51M
EBITDA$45.95M$137.75M$108.32M$113.89M$125.55M
EPS (basic)0.951.351.020.950.97
EPS (diluted)0.821.230.940.870.89
Weighted avg. shares (diluted)119.99M113.48M111.74M115.97M125.96M
Balance sheet
Cash & equivalents$120.50M$128.66M$135.55M$66.33M$77.62M
Short-term investments$251.66M$255.67M$232.67M$365.34M$145.92M
Receivables$59.79M$53.98M$41.12M$31.06M$27.62M
Inventory$12.87M$12.41M$7.73M$6.10M$4.99M
Current assets$485.46M$471.60M$458.64M$499.25M$266.46M
PP&E, net$1.89M$2.69M$195,000$633,000$1.00M
Total assets$836.65M$840.55M$621.52M$583.43M$423.76M
Current liabilities$166.09M$140.77M$104.50M$72.49M$47.54M
Total liabilities$188.85M$160.96M$114.81M$81.59M$47.95M
Shareholders' equity$647.80M$679.59M$506.70M$501.84M$375.81M
Shares outstanding105.97M105.11M103.41M107.83M105.94M
Cash flow statement
Operating cash flow$142.00M$198.29M$126.68M$120.32M$167.89M
Capital expenditure$211,000$2.17M$139,000$413,000$469,000
Free cash flow$141.78M$196.12M$126.54M$119.91M$167.42M
Investing cash flow$69.76M-$177.60M$90.91M-$114.33M$136.13M
Financing cash flow-$220.37M-$28.35M-$148.72M-$17.28M-$302.59M
Depreciation & amortization$1.15M$795,000$1.04M$1.26M$1.07M
Stock-based compensation$84.50M$61.35M$48.94M$42.44M$42.93M
Share buybacks$172.91M$15.66M$0$0—

Free plan shows the latest 5 periods; Pro shows all 26 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.